Company

ResApp Health Limited

Headquarters: Brisbane, QLD, Australia

Employees: 500

CEO: Dr. Anthony Keating

ASX: RAP -2.38%

Market Cap

A$176.2 Million

AUD as of Sept. 1, 2022

US$120.1 Million

Market Cap History

ResApp Health Limited market capitalization over time

Evolution of ResApp Health Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of ResApp Health Limited

Detailed Description

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

ResApp Health Limited has the following listings and related stock indices.


Stock: ASX: RAP wb_incandescent

Details

Headquarters:

100 Creek Street

Level 12

Brisbane, QLD 4000

Australia

Phone: 61 7 3724 0035